30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: Wright Medical

$120.4MM, -3% (U.S. $67.5MM, -3%, ex-U.S. $52.5MM, -3%)

OrthoRecon $64.0MM, -11% (U.S. -14%, ex-U.S. -8%)

  • Hip $35.4MM, -11% (U.S. -7%, ex-U.S. -12%)
  • Knee $27.8MM, -9% (U.S. -19%, ex-U.S. +1%)
  • Other $0.7MM, -35% (U.S. -48%, ex-U.S. -31%)

Extremities $56.2MM, +7% (U.S. +4%, ex-U.S. +15%)

  • Foot/Ankle $35.0MM, +19% (U.S. +17%, ex-U.S. +27%)
  • Upper Extremity $6.0MM, -6% (U.S. -7%, ex-U.S. -3%)
  • Biologics $13.6MM, -10% (U.S. -14%, ex-U.S. +5%)
  • Other $1.4MM, -1% (U.S. -22%, ex-U.S. +11%)

 

  • OrthoRecon still affected by U.S. customer losses, believed to have run their course
  • Completed acquisition of BioMimetic Therapeutics
  • Noting positive physician response to tissue-sparing SUPERPATH fast recovery hip technique, requires smaller incision and no hip dislocation
  • EVOLUTION knee launch well underway in Japan
  • Launching Wright Direct: offering clinically-proven hip and knee products at low prices, plus training and logistics support; will not be a rep in every case, and inventory is held by hospital; in exchange, price is negotiated to compensate the institution for taking on additional costs